Despite availability of many therapies indicated for bowel disorders, there is still an unmet need and heterogeneity among these patients, necessitating availability of a wide variety of therapeutics. Awareness of potential new products, their key benefits, and where they may fit into the treatment paradigm will be important when making decisions impacting patients and physicians, according to new analysis.
FDA issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer’s disease, before the onset of overt dementia.
FDA has alerted healthcare professionals that a counterfeit version of the cancer drug Avastin was distributed in the United States.
Because Tamiflu has been in short supply recently, pharmacists and other healthcare providers are being warned about confusion over emergency compounding of the drug.
The American Academy of Pediatrics (AAP) has published a policy statement to provide pediatricians with recommendations for assessing and treating Clostridium difficile infections (CDI) in children.
FDA’s approval of the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) could help alleviate shortages.
A majority of pharmacists and other healthcare practitioners believe that pharmacists need to disclose the source of high-risk compounded sterile preparations (CSPs) to prescribers, according to a recent survey.
The development and implementation of evidence-based appropriateness criteria may help reduce costs associated with an increase in elective procedures.
A think-tank report calls for national agenda to hold spending down to the growth in GDP per capita
ARBs and ACE inhibitors prolong life and help patients maintain daily living activities.
The new middle class represents an opportunity to sell health insurance products outside the United States
Hospitals have not gotten a break in the budget battles but few are changing their financial strategy
Among the list of changes that consumers simply are not ready to face is value-based purchasing and reduced care based on evidence
Quality rating processes will begin in 2016 for insurance exchanges, and iindustry groups recommend using current measures
In partnership with the Mayo Clinic, a UnitedHealthcare unit is putting data to work in a new facility to drive improved outcomes
Five key functions must be included in your provider-facing portal
Insurers see higher unit costs and increased utilization while HHS examines premium hikes
Navigators will be the boots on the ground helping millions of Americans enroll in exchange plans
Predictive analysis can link suspicious behavior back to fraudsters before claims are paid out
AHA notes that four out of five seniors have chronic conditions
The Medicaid program currently covers 60 million people, but it's about explode in terms of cost and enrollment
Canagliflozin is a sodium glucose co-transporter inhibitor under review for FDA approval for the treatment of type 2 diabetes mellitus.
Patients who take a combination of diuretics and either angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and add NSAIDs, have an increased risk of acute kidney injury, according to a study online in BMJ.
Polypharmacy screening has the significant potential to improve medication safety.
FDA and the Federal Trade Commission (FTC) issued a warning letter to Flu and Cold Defense LLC (Boca Raton, Fla.) for making misleading, unproven claims about its GermBullet inhaler, and said the company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.
FDA has approved mipomersen sodium (Kynamro, Genzyme and Isis Pharmaceuticals) once-a-week injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer drugs to reach patients and that their countries invest too little in fighting cancer, according a global survey.
Recent FDA action (through January 2013) related to, IPX066, Afatinib, Enobosam, GTx-024, Elafin, Ezatiostat HCL, Tranexamic acid tablets, Lamotrigine extended-release tablets
New molecular entity: A benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients age 2 years or older.
Recent FDA Approvals (through January 2013) related to (Deferasirox, Exjade, Novartis, bevacizumab, Avastin, Roche Group, trivalent influenza vaccine, Flublok, Protein Sciences, Budesonide, Uceris, Santarus, pooled plasma blood product, Octaplas, Octapharma, Sumatriptan iontophoretic transdermal system, Zecuity, NuPathe, onabotulinumtoxinA, Botox, Allergan